View Older Stories

Jun 30, 2026 04:01PM GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Jun 29, 2026 03:58PM GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Jun 25, 2026 03:49PM GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Jun 24, 2026 03:47PM GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Jun 23, 2026 03:36PM GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Jun 23, 2026 08:39AM GeneDx (WGS) PT Raised to $63 at Piper Sandler

Jun 22, 2026 02:03PM GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Jun 19, 2026 03:52PM GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Jun 18, 2026 03:51PM GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Jun 17, 2026 03:49PM GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Jun 16, 2026 03:47PM GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Jun 15, 2026 02:39PM GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Jun 12, 2026 05:29PM GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Jun 11, 2026 04:38PM GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Jun 10, 2026 04:53PM GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Jun 10, 2026 10:50AM TD Cowen notes short interest shifts in life science tools stocks

Jun 10, 2026 08:27AM Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of GeneDx Holdings Corp. (WGS)

Jun 9, 2026 03:44PM GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

May 11, 2026 01:57PM WGS: GeneDX Investors Should Contact Block & Leviton to Possibly Recover Losses

May 6, 2026 04:00PM GeneDX Holdings Investigated for Possible Securities Fraud; Investors Should Contact Block & Leviton to Recover Losses

May 5, 2026 07:51AM GeneDx (WGS) PT Lowered to $75 at Canaccord

May 5, 2026 05:42AM GeneDx (WGS) PT Lowered to $90 at BTIG, Removed from Top Pick List

May 4, 2026 04:08PM GeneDx Holdings (WGS) Misses Q1 EPS by 27c ; Offers Guidance

Apr 21, 2026 07:52AM Piper Sandler on GeneDx (WGS): 'Aggressively buy on any reset sell-off'

Apr 15, 2026 12:06PM Jefferies reiterates Buy on GeneDx (WGS) as analyst dismisses TAM saturation fears

Mar 31, 2026 09:37AM Piper Sandler Reiterates Overweight Rating on GeneDx (WGS)

Mar 18, 2026 03:26PM Jefferies Reiterates Buy Rating on GeneDx (WGS) on data moat, AI effeciency

Feb 24, 2026 05:19AM GeneDx (WGS) PT Lowered to $170 at BTIG

Feb 23, 2026 08:47AM Canaccord Genuity Reiterates Buy Rating on GeneDx (WGS)

Feb 23, 2026 08:47AM TD Cowen on GeneDx (WGS): '4Q First Look: 4Q & '26 Guide Match Preannouncement'

Feb 23, 2026 06:37AM GeneDx Holdings (WGS) Misses Q4 EPS by 70c ; Offers Guidance

Feb 9, 2026 05:28AM Wells Fargo Upgrades GeneDx (WGS) to Overweight

Jan 12, 2026 07:31AM GeneDx posts 41% revenue growth, issues 2026 guidance

Jan 8, 2026 08:32AM GeneDx partners with Komodo Health to create rare disease dataset

Jan 7, 2026 08:32AM GeneDx launches prenatal whole genome sequencing test

Dec 12, 2025 06:05AM BTIG: 'we name GH and WGS as 2026 Top Picks'

Oct 29, 2025 08:19AM GeneDx Holdings (WGS) Tops Q3 EPS by 8c; Offers Guidance

Oct 29, 2025 07:24AM GeneDx (WGS) PT Raised to $170 at Guggenheim

Oct 29, 2025 04:55AM GeneDx (WGS) PT Raised to $165 at BTIG

Oct 28, 2025 07:20AM GeneDx Holdings (WGS) files mixed shelf

Oct 20, 2025 08:00AM GeneDx receives FDA breakthrough device designation for genome tests

Oct 20, 2025 05:11AM Canaccord Genuity Starts GeneDx (WGS) at Buy

Oct 15, 2025 09:16AM Illumina constellation technology identifies hard-to-detect genetic variants

Oct 14, 2025 08:06AM GeneDx names Dr. Mimi Lee as chief precision medicine officer

Oct 1, 2025 04:01PM GeneDx joins $14.4 million NIH-funded genomic newborn screening study

Sep 30, 2025 08:00AM GeneDx names Lisa Gurry as chief business officer

Sep 11, 2025 07:54AM GeneDx (WGS) PT Raised at Piper Sandler; 'We Recommend Buying More on a Pullback'

Aug 4, 2025 10:19AM Piper Sandler on GeneDx (WGS): 'Visibility to a Multiyear Growth Cycle'

Jul 30, 2025 06:14AM GeneDx (WGS) PT Raised to $125 at BTIG

Jul 29, 2025 06:36AM GeneDx Holdings (WGS) Tops Q2 EPS by 38c ; Offers Guidance

View Older Stories